• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服焦谷氨酸钠的脑内渗透情况。

Brain penetration of orally administered sodium pyroglutamate.

作者信息

Chanal J L, Audran M, Sicard M T, Briley M

机构信息

Faculty of Pharmacy, University of Montpellier, France.

出版信息

J Pharm Pharmacol. 1988 Aug;40(8):584-5. doi: 10.1111/j.2042-7158.1988.tb05311.x.

DOI:10.1111/j.2042-7158.1988.tb05311.x
PMID:2907018
Abstract

The absorption and brain penetration of [3H]pyroglutamate was determined after oral administration to rats. Gas-liquid chromatography of the methylated derivatives followed by mass fragmentometry was used to analyse the plasma and brain levels of pyroglutamate. [3H]Pyroglutamate was separated from other labelled compounds by thin layer chromatography. The administration of 500 mg kg-1 [3H]pyroglutamate resulted in a 30-fold increase in plasma levels and a doubling in the brain levels. Over 60% of the cerebral radioactivity was present as [3H]pyroglutamate demonstrating that pyroglutamate is not only well absorbed but also penetrates in significant amounts into the brain.

摘要

给大鼠口服[³H]焦谷氨酸后,测定其吸收和脑渗透情况。采用甲基化衍生物的气-液色谱法,随后进行质谱分析,以分析焦谷氨酸的血浆和脑内水平。通过薄层色谱法将[³H]焦谷氨酸与其他标记化合物分离。给予500mg/kg[³H]焦谷氨酸后,血浆水平增加了30倍,脑内水平增加了一倍。超过60%的脑放射性以[³H]焦谷氨酸形式存在,这表明焦谷氨酸不仅吸收良好,而且大量渗透进入脑内。

相似文献

1
Brain penetration of orally administered sodium pyroglutamate.口服焦谷氨酸钠的脑内渗透情况。
J Pharm Pharmacol. 1988 Aug;40(8):584-5. doi: 10.1111/j.2042-7158.1988.tb05311.x.
2
Pyroglutamate kinetics and neurotoxicity studies in mice.小鼠中焦谷氨酸动力学与神经毒性研究
Toxicol Lett. 1983 May;16(3-4):225-9. doi: 10.1016/0378-4274(83)90180-7.
3
Plasma and brain levels of glutamate and pyroglutamate after oral monosodium glutamate to rats.
Toxicol Lett. 1982 Feb;10(2-3):169-75. doi: 10.1016/0378-4274(82)90070-4.
4
Presence of a particulate thyrotropin-releasing hormone-degrading pyroglutamate aminopeptidase activity in rat liver.大鼠肝脏中存在一种可降解促甲状腺激素释放激素的颗粒性焦谷氨酸氨基肽酶活性。
Neuroendocrinology. 1989 Apr;49(4):442-8. doi: 10.1159/000125150.
5
[Correlations of pharmacokinetics and pharmacodynamics of a combined preparation containing pyrrolidone and pyroglutamic acid].[含吡咯烷酮和焦谷氨酸的复方制剂的药代动力学与药效学相关性]
Eksp Klin Farmakol. 2006 Mar-Apr;69(2):58-61.
6
Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate.由谷氨酰胺形成细胞外谷氨酸:排除焦谷氨酸作为中间产物。
Brain Res. 2005 Aug 2;1052(1):88-96. doi: 10.1016/j.brainres.2005.06.014.
7
Comparison of penetration-enhancing ability of laurocapram, N-methyl-2-pyrrolidone and dodecyl-L-pyroglutamate.月桂氮䓬酮、N-甲基-2-吡咯烷酮和十二烷基-L-焦谷氨酸的促渗能力比较。
Pharm Weekbl Sci. 1988 Oct 14;10(5):189-92. doi: 10.1007/BF01956869.
8
Disposition and metabolism of double-labeled [3H and 14C] N-methyl-2-pyrrolidinone in the rat.双标记[3H和14C]N-甲基-2-吡咯烷酮在大鼠体内的处置与代谢
Drug Metab Dispos. 1988 Mar-Apr;16(2):243-9.
9
[Oleyl pyroglutamate for use as transdermal enhancer and its enhancing mechanism].[用作透皮促进剂的油酰焦谷氨酸及其促进机制]
Yao Xue Xue Bao. 2003 May;38(5):384-7.
10
Pyroglutamic aciduria: rate of formation and degradation of pyroglutamate.焦谷氨酸尿症:焦谷氨酸的生成和降解速率
Clin Chim Acta. 1973 Dec 27;49(3):311-23. doi: 10.1016/0009-8981(73)90227-1.

引用本文的文献

1
Saliva as a non-invasive matrix for assessing xenobiotic metabolites and metabolomes: implications for maternal health and preeclampsia.唾液作为评估外源性代谢物和代谢组的非侵入性基质:对孕产妇健康和先兆子痫的意义。
Int J Oral Sci. 2025 Jul 22;17(1):55. doi: 10.1038/s41368-025-00390-8.
2
Oxiracetam and D-pyroglutamic acid antagonize a disruption of passive avoidance behaviour induced by the N-methyl-D-aspartate receptor antagonist 2-amino-5-phosphonovalerate.奥拉西坦和D-焦谷氨酸可拮抗由N-甲基-D-天冬氨酸受体拮抗剂2-氨基-5-磷酸基戊酸诱导的被动回避行为障碍。
Psychopharmacology (Berl). 1990;100(1):130-1. doi: 10.1007/BF02245803.